Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by inforcashon Dec 13, 2007 10:40am
221 Views
Post# 14013897

RE: RE: Reimbursement

RE: RE: ReimbursementI guess I wasn't clear...I agree that $18 is good considering the entry points in the last 12 mths. I am also saying, like Everswan, if we can avoid being bought for 2 years, we will be even happier shareholders. Under my scenario, I am simply saying I don't want to see TH sell now, when TH could sell 24 months from now at a considerable premium. When I say sell I mean takeover as some have talked about lately. Partnering would be a similar situation (in that we lose some of the margins), though could increase market penetration if the partner has strong distribution channels. In the sell scenario we likely lose rights to all future indications--as you say---in the partnership we could 'separate' indications if we repackage them well...

By comaprison. If TH doesn't partner or sell, and the Stock were to jump to Christines median price of $18 by tomorrow, I think even a new investor at that level could realize 100% appreciate within a 2 year period. Either way, still great returns by any comparison.

Essentially, I'm arguing not to sell (be bought) now because there is so much more upside.

Hope that was clearer.

IFC
Bullboard Posts